What is Neuropace, Inc.'s gain (loss) on sale of investments?

Neuropace, Inc. (NPCE) reported gain (loss) on sale of investments of -$165K in Q1 2026.

How has Neuropace, Inc.'s gain (loss) on sale of investments changed year-over-year?

Neuropace, Inc.'s gain (loss) on sale of investments decreased by 101.2% year-over-year, from -$82K to -$165K.

Neuropace, Inc. NPCE Gain (Loss) on Sale of Investments

Gain (Loss) on Sale of Investments at other companies

ASI

Ategrity Specialty Insurance Company HoldingsASIC

$3.16M-54.8%

ProAssurancePRA

-$3.43M-102%

Teradyne, Inc.TER

-$3.32M+1.6%

NXP SemiconductorsNXPI

$1M+117%

Advanced Micro DevicesAMD

$85.25M—

eBayEBAY

$31M+1,650%

Other financials

Income statement

See full

Revenue$22.1M-2.0%

Gross profit$18.0M+4.1%

Operating income-$5.6M-8.2%

Net income-$6.7M-1.5%

EPS (diluted)-$0.20+4.8%

Balance sheet

See full

Cash & equivalents$15.6M-42.4%

Total debt$70.5M-3.7%

Total equity$14.5M-40.4%

Total assets$98.9M-10.3%

Cash flow

See full

Operating cash flow-$5.9M+21.1%

CapEx$117.0K+216%

Free cash flow-$6.0M+20.0%

Valuation

See full

Market cap$557.77M+63.4%

Enterprise value$612.6M+58.1%

P/S5.6×+1.6×

Profitability

See full

Gross margin78.3%+3.5pp

Operating margin-16.8%-3.5pp

Net margin-21.7%-4.5pp

FCF margin-10.3%-3.5pp

Returns & leverage

See full

Return on equity-111.4%-13.1pp

Debt / equity4.9×+1.9×

Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfInvestments.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s gain (loss) on sale of investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neuropace, Inc.'s gain (loss) on sale of investments?: Neuropace, Inc. (NPCE) reported gain (loss) on sale of investments of -$165K in Q1 2026.
How has Neuropace, Inc.'s gain (loss) on sale of investments changed year-over-year?: Neuropace, Inc.'s gain (loss) on sale of investments decreased by 101.2% year-over-year, from -$82K to -$165K.